BIOFIL CHEMICALS & PHARMACEUTICALS
|
|
BOM : 524396     NSE : BIOFILCHEM     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Good [Stock is Cheap] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : NA |
Apr 24,2024 |
Price(EOD): ₹ 72.66
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 118.44 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
BIOFIL CHEMICALS & PHARMACEUTICALS | NA | NA | NA |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
FUNDAMENTAL ANALYSIS OF BIOFIL CHEMICALS & PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF BIOFIL CHEMICALS & PHARMACEUTICALS
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
176.76
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 0.67 Cr
[Latest Qtr - Dec2023 - Standalone Results ] 6.83
P/B Calculated based on Book Value of Rs 17.30 Cr
[Latest Year - Mar2023 - Standalone Results ] 3.08
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2023 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
8% -36% -36% |
SHARE PRICE MOMENTUM OF BIOFIL CHEMICALS & PHARMACEUTICALS
BIOFIL CHEMICALS & PHARMACEUTICALS vs SENSEX
DEBT OF BIOFIL CHEMICALS & PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0.03 0.03 0.03 0.03 |
- - - - |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF BIOFIL CHEMICALS & PHARMACEUTICALS
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF BIOFIL CHEMICALS & PHARMACEUTICALS
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-71.03% -19.25% -26.14% -24.39% |
236.81% -14.98% -15.04% -6.06% |
QtrlyTrend |
-6 | |
Latest Qtr: Dec2023 | ||
Quarterly Result Analysis → |
BIOFIL CHEMICALS & PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about BIOFIL CHEMICALS & PHARMACEUTICALS
Is BIOFIL CHEMICALS & PHARMACEUTICALS good for long term investment?
As on Apr 24,2024, the Fundamentals of BIOFIL CHEMICALS & PHARMACEUTICALS look Poor and hence it may not be good for long term investment ! See Financial Performance of BIOFIL CHEMICALS & PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is BIOFIL CHEMICALS & PHARMACEUTICALS UnderValued or OverValued?
As on Apr 24,2024, BIOFIL CHEMICALS & PHARMACEUTICALS is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of BIOFIL CHEMICALS & PHARMACEUTICALS ?
As on Apr 24,2024, the Intrinsic Value of BIOFIL CHEMICALS & PHARMACEUTICALS is Rs. 112.84 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 67.30
Fair Value [Median EV / Sales Model] : Rs. 112.84
Fair Value [Median Price / Sales Model] : Rs. 112.97
Estimated Median Fair Value of BIOFIL CHEMICALS & PHARMACEUTICALS : Rs. 112.84
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.